AbbVie (NYSE:ABBV) recently announced positive results from its Phase 3 TEMPLE study, marking significant progress in ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes younger patients and those with acute HCV. This development is ...

Mavyret (glecaprevir and pibrentasvir) is a prescription drug that’s used to treat hepatitis C. Mavyret comes as oral tablets and pellets, which are swallowed. Mavyret is used in certain adults ...

Mavyret (glecaprevir/pibrentasvir) is a prescription brand-name medication. It’s approved by the Food and Drug Administration (FDA) to treat certain forms of ...

If you have hepatitis C, your doctor may prescribe an antiviral medication, such as Mavyret (glecaprevir and pibrentasvir) or Epclusa (velpatasvir and sofosbuvir). Hepatitis C is an infection ...

Mavyret (glecaprevir/pibrentasvir) is a prescription brand-name medication. The Food and Drug Administration (FDA) has approved it to treat certain forms of hepatitis ...